{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:32:55Z","timestamp":1786980775008,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10549-024-07586-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:39:52Z","timestamp":1737502792000},"page":"487-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan"],"prefix":"10.1007","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6722-9258","authenticated-orcid":false,"given":"Julie","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Scholand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Crossno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Hummert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Jeppson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saundra","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"7586_CR1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969\u20132022) (www.seer.cancer.gov\/popdata), National Cancer Institute, DCCPS, Surveillance Research Program, released March 2024."},{"key":"7586_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1200\/JCO.1998.16.4.1340","volume":"16","author":"IL Andrulis","year":"1998","unstructured":"Andrulis IL, Bull SB, Blackstein ME et al (1998) neu\/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340\u20131349. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1340","journal-title":"J Clin Oncol"},{"key":"7586_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H et al (2024) HER2-targeted therapies in cancer: a systematic review. Biomark Res 12:16. https:\/\/doi.org\/10.1186\/s40364-024-00565-1","journal-title":"Biomark Res"},{"key":"7586_CR4","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951\u20131962. https:\/\/doi.org\/10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"7586_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386:1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"7586_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung W-P et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401:105\u2013117. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5","journal-title":"Lancet"},{"key":"7586_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"7586_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim S-B et al (2023) Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773\u20131785. https:\/\/doi.org\/10.1016\/S0140-6736(23)00725-0","journal-title":"Lancet"},{"key":"7586_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"7586_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101613","volume":"8","author":"LR Soares","year":"2023","unstructured":"Soares LR, Vilbert M, Rosa VDL et al (2023) Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis. ESMO Open 8:101613. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101613","journal-title":"ESMO Open"},{"key":"7586_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","volume":"19","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Crossno CL, Gesthalter YB et al (2023) Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 19:539\u2013546. https:\/\/doi.org\/10.1200\/OP.22.00480","journal-title":"JCO Oncol Pract"},{"key":"7586_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553","volume":"7","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bianchini G, Cortes J et al (2022) Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 7:100553. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553","journal-title":"ESMO Open"},{"key":"7586_CR13","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.3390\/curroncol30090582","volume":"30","author":"J-W Henning","year":"2023","unstructured":"Henning J-W, Brezden-Masley C, Gelmon K et al (2023) Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective. Curr Oncol 30:8019\u20138038. https:\/\/doi.org\/10.3390\/curroncol30090582","journal-title":"Curr Oncol"},{"key":"7586_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102043","volume":"8","author":"D Wekking","year":"2023","unstructured":"Wekking D, Porcu M, Pellegrino B et al (2023) Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open 8:102043. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102043","journal-title":"ESMO Open"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07586-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T22:36:20Z","timestamp":1742769380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7586"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07586-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK received honoraria from the Binaytara Foundation for speaking at conferences, worked as a consultant on an advisory board for Immunogen, and is currently a member of Immunogen\u2019s 2024 Speaker\u2019s Bureau. All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An informed consent waiver was granted for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}